TRCN-1023

DRUG2 trials

Sponsors

Trace Neuroscience Inc., Trace Neuroscience, Inc.

Conditions

Amyotrophic Lateral SclerosisAmyotrophic lateral sclerosis

Phase 1

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 / 2 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Single Ascending Doses of TRCN-1023 Administered by Intrathecal Injections to Adult People Living with Amyotrophic Lateral Sclerosis

Not yet recruitingCTIS2025-523111-11-00

Trace Neuroscience Inc.Amyotrophic lateral sclerosis

Target: 6Updated: 2026-06-22

FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

RecruitingNCT07674667

Trace Neuroscience, Inc.Amyotrophic Lateral Sclerosis

Start: 2026-08-20End: 2027-09-01Target: 30Updated: 2026-09-09